When Lilly acquired Ajax Therapeutics for up to $2.3 billion in April, the deal was a bet on a Phase 1 asset with no clinical data. Lilly Oncology president Jake Van Naarden told investors that proof-of-concept data would come later in 2026. It arrived on June 13. Fierce Biotech reported that early data from the novel Type II JAK2 inhibitor showed the drug “started working right out of the gate, with a good safety profile.” This is the first clinical validation that binding JAK2 in the Type II (inactive) conformation—rather than the Type I (active) conformation used by all approved JAK2 inhibitors—produces meaningful clinical activity in myelofibrosis patients. This is Lilly’s 12-deal, $30 billion-plus M&A strategy producing its first clinical proof point beyond the GLP-1 franchise. Meanwhile, AstraZeneca landed the first and only targeted treatment for PTEN-deficient metastatic prostate cancer with the Truqap approval on June 13—a precision medicine milestone in a tumor type where biomarker-driven treatment has been limited. Kardigan Therapeutics set IPO terms at up to $373 million for a cardiovascular pipeline. EHA 2026 wrapped in Stockholm. And Sensorion exited hearing loss gene therapy after Regeneron’s Otarmeni approval changed the competitive landscape.
Top Story: Ajax JAK2 Inhibitor Shows Early Clinical Activity in Myelofibrosis
What Happened: Fierce Biotech reported on June 13 that early data from Lilly’s Ajax Therapeutics Type II JAK2 inhibitor (AJ1-11095) showed the drug “started working right out of the gate, with a good safety profile.” Lilly Oncology president Jake Van Naarden shared the results.
Why Type II Matters
AJ1-11095 is a first-in-class oral once-daily inhibitor that binds the Type II (inactive) conformation of JAK2. This is a fundamentally different binding mode from every approved JAK2 inhibitor on the market. Ruxolitinib, fedratinib, pacritinib, and momelotinib all bind the Type I (active) conformation of JAK2. These drugs have been the standard of care for myelofibrosis for years and have improved outcomes for thousands of patients. But they share a common limitation: patients develop resistance over time as the disease evolves, and once resistance to Type I JAK2 inhibition develops, there is no approved therapy that addresses it.
The Type II binding mode is designed to overcome this exact problem. By binding JAK2 in its inactive conformation, AJ1-11095 engages the target through a different structural mechanism than Type I inhibitors. Patients whose disease has become resistant to ruxolitinib or other approved JAK2 inhibitors may still respond to a Type II approach because the resistance mutations that block Type I binding do not necessarily block Type II binding.
The Phase 1 AJX-101 trial is enrolling myelofibrosis patients who have been previously treated with a Type I JAK2 inhibitor—precisely the resistance population where unmet need is greatest. Van Naarden’s characterization of the drug as “working right out of the gate” suggests that clinical activity was observed early in treatment, which is an encouraging signal for a drug in its first human testing.
What This Means for Lilly’s M&A Thesis
The Ajax data are the first clinical proof point from Lilly’s 12-deal, $30 billion-plus acquisition campaign that validates an investment thesis beyond the GLP-1 franchise. Lilly paid up to $2.3 billion for Ajax based on preclinical data and the mechanistic rationale for Type II JAK2 inhibition. The early clinical activity confirms that the mechanism works in humans—the single most important risk-reduction milestone in any drug’s development.
This does not guarantee success. Phase 1 proof-of-concept data must translate through dose optimization, registrational trial design, and ultimately a pivotal study demonstrating sufficient efficacy and safety for FDA approval. But the distance between “we believe this will work” and “it is working in patients” is the most consequential gap in drug development. Ajax has crossed it.
For Lilly’s broader M&A narrative, the Ajax validation provides management with a data point to cite when investors ask whether $30 billion in acquisitions is producing results. Kelonia’s in vivo CAR-T data at ASCO (which Fierce Biotech said “justified” the $3.2 billion price tag) was the first validation. Ajax is the second. Each clinical data readout from Lilly’s acquired pipeline either builds confidence in the M&A strategy or raises questions about it. So far, the early signals are positive.
Our Pro brief analyzes what “working right out of the gate” means for the registrational development timeline, how the Type II mechanism addresses the myelofibrosis resistance landscape, and what the proof-of-concept data imply for Lilly’s $2.3B investment. [Details below.]
AstraZeneca Truqap Approved as First Targeted Treatment for PTEN-Deficient Prostate Cancer
What Happened: The FDA approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone on June 13 for adult patients with PTEN-deficient metastatic castration-sensitive prostate cancer. This is the first and only targeted treatment approved for this molecularly defined prostate cancer population.
Why PTEN Matters in Prostate Cancer
PTEN is a tumor suppressor gene. When PTEN is lost or inactivated—a phenomenon called PTEN deficiency—the PI3K/AKT signaling pathway becomes overactive, driving tumor growth and resistance to standard hormonal therapies. PTEN loss occurs in a significant proportion of metastatic prostate cancers and has historically been associated with worse outcomes. But until now, there was no treatment that specifically targeted this molecular alteration. Oncologists knew which patients had PTEN loss, but they could not act on that knowledge with a targeted therapy.
Truqap changes that. As an AKT inhibitor, capivasertib directly targets the PI3K/AKT pathway that is activated by PTEN deficiency. When combined with abiraterone (which blocks androgen production) and prednisone, the combination addresses both the hormonal driver of prostate cancer growth and the molecular escape mechanism that PTEN-deficient tumors use to evade hormonal therapy.
The Companion Diagnostic Requirement
The approval creates a companion diagnostic requirement for PTEN testing. Physicians treating metastatic prostate cancer will now need to order PTEN testing to identify patients who are eligible for the Truqap combination. This is the first time prostate cancer treatment has been stratified by a molecular biomarker beyond androgen receptor status, and it changes the clinical workflow for every oncologist managing metastatic prostate cancer.
For the diagnostics sector, the PTEN testing requirement creates a new reimbursable clinical standard. Every metastatic prostate cancer patient becomes a candidate for PTEN assessment, expanding the volume of genomic testing in a tumor type that has historically relied less on biomarker-driven treatment selection than breast or lung cancer. The diagnostics opportunity is substantial: prostate cancer is the most common cancer in men, and metastatic disease affects tens of thousands of patients annually in the United States alone. Adding PTEN testing to the diagnostic workflow for every one of those patients creates meaningful incremental volume for genomic testing providers.
The Truqap approval follows J&J’s Erleada PROTEUS data at ASCO (perioperative prostate cancer, “125-year paradigm shift”) and reinforces that prostate cancer is undergoing a treatment revolution in 2026. The disease is being reshaped on two fronts simultaneously: earlier intervention through perioperative therapy (PROTEUS) and molecular precision through biomarker-matched targeted treatment (Truqap/PTEN). For oncologists managing prostate cancer, the treatment algorithm is more complex than it was six months ago—but the outcomes for patients are substantially better.
Kardigan Sets IPO Terms at $373M for Cardiac Drug Pipeline
What Happened: Kardigan Therapeutics set terms for an IPO that could raise up to $373 million. The company would be the 13th biotech to go public in 2026.
Why This Matters: Kardigan’s cardiovascular focus is notable because cardiac biotechs have been underrepresented in the 2026 IPO wave, which has been dominated by oncology and metabolic disease companies. The ability to raise $373 million for a cardiovascular pipeline signals that investor appetite for the cardiac space is growing.
The cardiovascular investment thesis has strengthened throughout 2026. AstraZeneca’s Baxfendy was approved as the first new hypertension mechanism in two decades ($5 billion peak sales projected). The AHA/ACC issued new LDL cholesterol guidelines expanding addressable populations. Bayer’s asundexian NDA was accepted as the first Factor XIa inhibitor for stroke prevention. BridgeBio’s Attruby is challenging Pfizer’s tafamidis in ATTR-CM. And Verve’s base editing data showed the potential for permanent cholesterol reduction through a single treatment.
Each development adds clinical and commercial validation to the cardiovascular space. After years of underinvestment relative to oncology and metabolic disease—driven by the perception that cardiovascular drug development was too risky, too expensive, and too crowded—the sector is experiencing a renaissance driven by genuinely novel mechanisms that address unmet needs in large patient populations. Kardigan’s IPO signals that public market investors are now willing to fund cardiac innovation at valuations comparable to what oncology companies have traditionally commanded. A successful Kardigan debut would encourage additional cardiovascular-focused biotechs to consider the public markets, further building the pipeline of innovation in a therapeutic area that affects more patients globally than any other.
EHA 2026 Wrap: AbbVie Venetoclax Data
The European Hematology Association congress wrapped up in Stockholm (June 11 to 14). AbbVie presented new Phase 3 data on a fixed-duration venetoclax-based combination in hematologic malignancies. Venetoclax (Venclexta) is a cornerstone of AbbVie’s hematology franchise and continues to expand its label through new combination regimens and fixed-duration treatment protocols that appeal to both patients (who prefer time-limited treatment) and payers (who prefer predictable costs over open-ended therapy).
EHA also featured updates on CAR-T real-world outcomes, bispecific antibodies in myeloma, and emerging cell therapies. The hematology conference season (EHA followed by ASH in December) provides the clinical data calendar that drives treatment decisions across blood cancers for the following year.
For AbbVie, the venetoclax data reinforce the drug’s position as the backbone of chronic lymphocytic leukemia and acute myeloid leukemia treatment. Fixed-duration regimens—where patients take the drug for a defined period rather than indefinitely—have become increasingly important in hematology because they reduce both the long-term side-effect burden on patients and the cumulative cost to payers. Each new combination dataset that demonstrates efficacy with a fixed treatment duration expands venetoclax’s addressable population and strengthens AbbVie’s franchise as the post-Humira transition continues. The Rinvoq patent settlement (extending exclusivity to 2037) and the Skyrizi growth trajectory provide the immunology foundation, while venetoclax provides the hematology foundation. Together, they form the pillars of AbbVie’s post-Humira growth story.
Sensorion Exits Hearing Loss Gene Therapy After Otarmeni Approval
What Happened: Sensorion ended development of its gene therapy for OTOF-related hearing loss, citing a “notably changed” development environment. The change is directly attributable to Regeneron’s Otarmeni, approved under CNPV in April as the first gene therapy for genetic hearing loss.
Why This Matters: Sensorion’s exit illustrates a dynamic that plays out repeatedly in rare disease drug development: once a first-mover secures approval and establishes the treatment paradigm, fast-follower programs can become unviable. The regulatory bar rises because the FDA now has an approved comparator that any new entrant must match or beat. The clinical trial enrollment challenge increases because patients and physicians prefer the approved therapy to an experimental one. And the commercial opportunity shrinks because the first-mover captures the most motivated patients and builds the physician relationships that define prescribing patterns in small markets.
Sensorion’s decision to withdraw rather than compete against an approved product is a rational allocation of resources—but it means the OTOF hearing loss space will be served by a single therapy for the foreseeable future. For the CNPV program, which accelerated Otarmeni’s approval, the Sensorion exit raises an interesting policy question: does accelerating the first approval in a rare disease inadvertently reduce the competitive innovation that might produce better treatments for patients over time?
Strategic Themes
1. Lilly’s M&A Strategy Is Starting to Produce Clinical Data Beyond GLP-1
Ajax proof-of-concept data in myelofibrosis. Kelonia in vivo CAR-T data at ASCO. Two of Lilly’s 12 acquisitions have now generated their first clinical validation. These early signals matter because they begin to answer the question that has hung over Lilly’s $30 billion-plus deal campaign: can the company convert financial capital into clinical progress at this scale and pace? The data so far say yes—but 10 more acquisitions still await their first clinical readouts. The December 7 Investment Community Meeting will be the forum where Lilly presents the full clinical development timeline across all 12 programs.
2. Precision Oncology in Prostate Cancer Just Took a Major Step Forward
PTEN-deficient prostate cancer now has its first targeted therapy. Combined with the PROTEUS perioperative data from ASCO, prostate cancer treatment is being reshaped on two fronts simultaneously: earlier intervention and molecular precision. The companion diagnostic requirement for PTEN testing will expand genomic profiling in prostate cancer, which has historically lagged behind breast and lung cancer in biomarker-driven treatment selection.
3. The 13th IPO of 2026 Is in Cardiovascular—and That Matters
Twelve of the first thirteen biotech IPOs in 2026 have been dominated by oncology and metabolic disease. Kardigan’s cardiovascular focus at $373 million signals that the cardiac space is attracting the capital it needs to sustain a development pipeline. The cardiovascular renaissance we have tracked throughout the year—Baxfendy, asundexian, Attruby, Verve, new LDL guidelines—is now producing its own IPO cycle.
4. First-Mover Advantage in Rare Disease Can Make Follow-On Programs Unviable
Sensorion’s exit from OTOF hearing loss gene therapy after Otarmeni’s CNPV approval is a case study in competitive dynamics. The CNPV program, designed to accelerate approvals for national priorities, produces a first-mover advantage so significant that it can eliminate competitive programs entirely. This is good for patients (faster access to the first therapy) but raises questions about whether the acceleration comes at the cost of long-term therapeutic competition and innovation in small markets.
Frequently Asked Questions
What did the Ajax data show?
Lilly’s Type II JAK2 inhibitor (AJ1-11095) “started working right out of the gate, with a good safety profile” in myelofibrosis patients who had previously been treated with Type I JAK2 inhibitors. This is the first clinical validation of the Type II JAK2 binding mechanism.
What is Truqap?
AstraZeneca’s capivasertib, an AKT inhibitor. Approved June 13 as the first targeted treatment for PTEN-deficient metastatic prostate cancer. Combined with abiraterone and prednisone. Creates a companion diagnostic requirement for PTEN testing.
What is the Kardigan IPO?
Up to $373 million for a clinical-stage cardiovascular biotech. Would be the 13th biotech IPO of 2026. Notable as the first significant cardiovascular-focused IPO in the current cycle.
Why did Sensorion exit hearing loss gene therapy?
Regeneron’s Otarmeni was approved under CNPV in April for the same indication (OTOF-related hearing loss). The approval changed the competitive and regulatory landscape, making Sensorion’s follow-on program unviable.
What happened at EHA?
AbbVie presented Phase 3 venetoclax combination data in hematologic malignancies. The conference (Stockholm, June 11 to 14) also featured CAR-T real-world evidence, bispecific antibody updates, and emerging cell therapy data.
When is BIO International?
Next week, June 22 to 25 in San Diego. The industry’s largest partnering event.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Type II JAK2. We analyze what “working right out of the gate” means for the registrational development timeline, how the Type II mechanism addresses the myelofibrosis resistance landscape that current therapies cannot, and what the proof-of-concept data imply for the durability of Lilly’s $2.3B investment thesis.
PTEN-Deficient Prostate Cancer. We assess how Truqap opens a precision oncology market in prostate cancer, what the companion diagnostic requirement means for genomic testing companies, and how the PTEN biomarker changes the clinical workflow for metastatic prostate cancer management.
Cardiovascular IPOs. We analyze why Kardigan at $373M signals renewed investor interest in the cardiac space, compile the cardiovascular catalysts that are building the investment case, and assess whether cardiac biotech valuations are reaching parity with oncology.
Plus: EHA venetoclax franchise analysis, Sensorion/Otarmeni competitive dynamics, Ajax registrational trial design preview, and the updated catalyst calendar through H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
